a Laboratory of Precision NanoMedicine, School of Molecular Cell Biology and Biotechnology , George S. Wise Faculty of Life Sciences, Tel Aviv University , Tel Aviv , Israel.
b Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering , Tel Aviv University , Tel Aviv , Israel.
J Drug Target. 2019 Jun-Jul;27(5-6):542-554. doi: 10.1080/1061186X.2018.1533556. Epub 2018 Oct 18.
One of the major challenges in drug development is the delivery of therapeutics to the central nervous system (CNS). The blood-brain barrier (BBB), which modulates the passage of molecules from the CNS, presents a formidable obstacle that limits brain uptake of therapeutics and, therefore, impedes the treatment of multiple neurological pathologies. Targeted nanocarriers present an excellent opportunity for drug delivery into the brain leveraging on endogenous receptors to transport therapeutics across the BBB endothelium. Receptor-mediated transport endows multiple benefits over other conventional delivery methods such as the transient permeabilization of the BBB or the direct depositioning of intracranial depots. Herein, different strategies for nanocarrier targeting to the CNS are discussed, highlighting the challenges and recent developments.
药物开发面临的主要挑战之一是将治疗药物递送到中枢神经系统（CNS）。血脑屏障（BBB）调节 CNS 中分子的通过，这是一个巨大的障碍，限制了治疗药物进入大脑，从而阻碍了多种神经病理学的治疗。靶向纳米载体为药物递送到大脑提供了极好的机会，利用内源性受体将治疗药物穿过 BBB 内皮细胞进行运输。与 BBB 的瞬时通透性或颅内沉积的直接沉积等其他传统递药方法相比，受体介导的递药具有多种优势。本文讨论了 CNS 靶向纳米载体的不同策略，重点介绍了挑战和最新进展。
